Non–clinical efficacy, safety and stable clinical cell processing of induced pluripotent stem cell‐derived anti–glypican‐3 chimeric antigen receptor‐expressing natural killer/innate lymphoid cells

The use of allogeneic, pluripotent stem‐cell‐derived immune cells for cancer immunotherapy has been the subject of recent clinical trials. In Japan, investigator‐initiated clinical trials will soon begin for ovarian cancer treatment using human leukocyte antigen (HLA)‐homozygous‐induced pluripotent...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer science 2020-05, Vol.111 (5), p.1478-1490
Hauptverfasser:	Ueda, Tatsuki, Kumagai, Ayako, Iriguchi, Shoichi, Yasui, Yutaka, Miyasaka, Tadayo, Nakagoshi, Kengo, Nakane, Kazuki, Saito, Keigo, Takahashi, Mari, Sasaki, Aki, Yoshida, Shinsuke, Takasu, Naoko, Seno, Hiroshi, Uemura, Yasushi, Tamada, Koji, Nakatsura, Tetsuya, Kaneko, Shin
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies Antigens Cancer immunotherapy Cancer therapies CD45 antigen CD7 antigen Cell differentiation chimeric antigen receptor Chimeric antigen receptors Clinical trials Cytotoxicity GPC3 Heparan sulfate proteoglycans Histocompatibility antigen HLA ILC Immunodeficiency Immunotherapy Interferon iPSC Liver cancer Lymphatic system Lymphocytes Lymphoid cells Manufacturers Natural killer cells Original Ovarian cancer Ovaries Pluripotency Quality control Safety Stem cell transplantation Stem cells Tumor cells Tumorigenicity Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!